Photocure ASA (PHO) - Financial and Strategic SWOT Analysis Review
Photocure ASA (PHO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Photocure ASA (Photocure) is a specialty pharmaceutical company with focus on bladder cancer. It develops and markets pharmaceuticals for the diagnosis and treatment of bladder cancer and precancerous conditions based on its photodynamic technology. The company’s flagship product Hexvix is an intravesical solution used for the detection of bladder cancer. The company offers this product under the name Cysview in the US for the use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder. Photocure’s pipeline products include Cevira, a photodynamic drug-device combination product in the Phase II clinical studies for the treatment of HPV infection and precancerous lesions of the cervix. The company sells product directly through its own specialty and medical teams in the US and Nordic and through partnerships with Juno Pharmaceuticals and BioSyent Pharma.in Canada and Australia, New Zealand. Photocure is headquartered in Oslo, Norway.
Photocure ASA Key Recent Developments
Sep 15,2021: Photocure: Presentations of Blue Light flexible cystoscopy study results and bladder cancer surgical techniques featured at AUA 2021
Sep 01,2021: Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development
Aug 11,2021: Photocure : Results for the second quarter of 2021
Aug 11,2021: Photocure Announces Results for the second quarter of 2021
Jul 13,2021: Photocure: New data presented at EAU 2021 highlight the effects of blue light cystoscopy on detection and recurrence of bladder cancer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Photocure ASA (Photocure) is a specialty pharmaceutical company with focus on bladder cancer. It develops and markets pharmaceuticals for the diagnosis and treatment of bladder cancer and precancerous conditions based on its photodynamic technology. The company’s flagship product Hexvix is an intravesical solution used for the detection of bladder cancer. The company offers this product under the name Cysview in the US for the use in the cystoscopic detection of non-muscle invasive papillary cancer of the bladder. Photocure’s pipeline products include Cevira, a photodynamic drug-device combination product in the Phase II clinical studies for the treatment of HPV infection and precancerous lesions of the cervix. The company sells product directly through its own specialty and medical teams in the US and Nordic and through partnerships with Juno Pharmaceuticals and BioSyent Pharma.in Canada and Australia, New Zealand. Photocure is headquartered in Oslo, Norway.
Photocure ASA Key Recent Developments
Sep 15,2021: Photocure: Presentations of Blue Light flexible cystoscopy study results and bladder cancer surgical techniques featured at AUA 2021
Sep 01,2021: Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development
Aug 11,2021: Photocure : Results for the second quarter of 2021
Aug 11,2021: Photocure Announces Results for the second quarter of 2021
Jul 13,2021: Photocure: New data presented at EAU 2021 highlight the effects of blue light cystoscopy on detection and recurrence of bladder cancer
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Photocure ASA - Key Facts
Photocure ASA - Key Employees
Photocure ASA - Key Employee Biographies
Photocure ASA - Major Products and Services
Photocure ASA - History
Photocure ASA - Company Statement
Photocure ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Photocure ASA - Business Description
Business Segment: Commercial Franchise
Overview
Performance
Business Segment: Development Portfolio
Overview
Performance
Geographical Segment: Austria
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Nordic countries
Performance
Geographical Segment: Other European Countries
Performance
Geographical Segment: Partner Countries Europe
Performance
Geographical Segment: Partner Countries Rest of World
Performance
Geographical Segment: The Netherlands
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
Photocure ASA - Corporate Strategy
Photocure ASA - SWOT Analysis
SWOT Analysis - Overview
Photocure ASA - Strengths
Photocure ASA - Weaknesses
Photocure ASA - Opportunities
Photocure ASA - Threats
Photocure ASA - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Photocure ASA, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 15, 2021: Photocure: Presentations of Blue Light flexible cystoscopy study results and bladder cancer surgical techniques featured at AUA 2021
Sep 01, 2021: Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development
Aug 11, 2021: Photocure : Results for the second quarter of 2021
Aug 11, 2021: Photocure Announces Results for the second quarter of 2021
Jul 13, 2021: Photocure: New data presented at EAU 2021 highlight the effects of blue light cystoscopy on detection and recurrence of bladder cancer
Jun 23, 2021: Photocure: New article published in Urologic Oncology: Macro and Microeconomics of Blue Light Cystoscopy with Cysview in non-muscle-invasive bladder cancer
May 19, 2021: Photocure : Results for the first quarter of 2021
Mar 03, 2021: Photocure ASA: Results for the fourth quarter of 2020
Feb 24, 2021: Photocure ASA: Invitation to presentation of fourth quarter and preliminary full year 2020 financial results
Nov 10, 2020: Photocure: Results for the third quarter of 2020
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Photocure ASA - Key Facts
Photocure ASA - Key Employees
Photocure ASA - Key Employee Biographies
Photocure ASA - Major Products and Services
Photocure ASA - History
Photocure ASA - Company Statement
Photocure ASA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Photocure ASA - Business Description
Business Segment: Commercial Franchise
Overview
Performance
Business Segment: Development Portfolio
Overview
Performance
Geographical Segment: Austria
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Nordic countries
Performance
Geographical Segment: Other European Countries
Performance
Geographical Segment: Partner Countries Europe
Performance
Geographical Segment: Partner Countries Rest of World
Performance
Geographical Segment: The Netherlands
Performance
Geographical Segment: The UK
Performance
Geographical Segment: The US
Performance
Photocure ASA - Corporate Strategy
Photocure ASA - SWOT Analysis
SWOT Analysis - Overview
Photocure ASA - Strengths
Photocure ASA - Weaknesses
Photocure ASA - Opportunities
Photocure ASA - Threats
Photocure ASA - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Photocure ASA, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Sep 15, 2021: Photocure: Presentations of Blue Light flexible cystoscopy study results and bladder cancer surgical techniques featured at AUA 2021
Sep 01, 2021: Photocure appoints Anders Neijber as Vice President, Global Medical Affairs and Clinical Development
Aug 11, 2021: Photocure : Results for the second quarter of 2021
Aug 11, 2021: Photocure Announces Results for the second quarter of 2021
Jul 13, 2021: Photocure: New data presented at EAU 2021 highlight the effects of blue light cystoscopy on detection and recurrence of bladder cancer
Jun 23, 2021: Photocure: New article published in Urologic Oncology: Macro and Microeconomics of Blue Light Cystoscopy with Cysview in non-muscle-invasive bladder cancer
May 19, 2021: Photocure : Results for the first quarter of 2021
Mar 03, 2021: Photocure ASA: Results for the fourth quarter of 2020
Feb 24, 2021: Photocure ASA: Invitation to presentation of fourth quarter and preliminary full year 2020 financial results
Nov 10, 2020: Photocure: Results for the third quarter of 2020
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Photocure ASA, Key Facts
Photocure ASA, Key Employees
Photocure ASA, Key Employee Biographies
Photocure ASA, Major Products and Services
Photocure ASA, History
Photocure ASA, Subsidiaries
Photocure ASA, Key Competitors
Photocure ASA, Ratios based on current share price
Photocure ASA, Annual Ratios
Photocure ASA, Annual Ratios (Cont...1)
Photocure ASA, Annual Ratios (Cont...2)
Photocure ASA, Interim Ratios
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Photocure ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Photocure ASA, Key Facts
Photocure ASA, Key Employees
Photocure ASA, Key Employee Biographies
Photocure ASA, Major Products and Services
Photocure ASA, History
Photocure ASA, Subsidiaries
Photocure ASA, Key Competitors
Photocure ASA, Ratios based on current share price
Photocure ASA, Annual Ratios
Photocure ASA, Annual Ratios (Cont...1)
Photocure ASA, Annual Ratios (Cont...2)
Photocure ASA, Interim Ratios
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Photocure ASA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Photocure ASA, Performance Chart (2016 - 2020)
Photocure ASA, Ratio Charts
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Photocure ASA, Performance Chart (2016 - 2020)
Photocure ASA, Ratio Charts
Photocure ASA, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Photocure ASA, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021